公开(公告)号：US20240277803A1

公开(公告)日：2024-08-22

申请号：US18439331

申请日：2024-02-12

Applicant: Minerva Biotechnologies Corporation

Inventor： Cynthia Bamdad ,  Benoit Smagghe

IPC: A61K38/17 ,  A01K67/0271 ,  A61K38/45 ,  A61K39/395 ,  A61K49/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C07K16/30 ,  C07K16/40 ,  C12N9/12 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K38/1735 ,  A61P35/00 ,  A01K67/0271 ,  A01K2267/0331 ,  A61K38/45 ,  A61K39/3955 ,  A61K49/0008 ,  C07K14/4727 ,  C07K16/18 ,  C07K16/3092 ,  C07K16/40 ,  C12N9/1229 ,  C12Y207/04006 ,  G01N33/5073 ,  G01N33/574 ,  G01N2333/71 ,  G01N2500/10 ,  G01N2800/56

Abstract: The present application discloses inhibitors of NME family of proteins.

公开(公告)号：US12037651B2

公开(公告)日：2024-07-16

申请号：US17727465

申请日：2022-04-22

Applicant: Gnubiotics Sciences SA

Inventor： Adeyemi Adesokan

IPC: C12Q1/689 ,  A23K10/18 ,  A23K50/40 ,  A61K9/00 ,  A61K35/741 ,  A61K35/742 ,  A61K38/17 ,  A61P3/04 ,  C12Q1/02 ,  A61K35/00

CPC classification number: C12Q1/689 ,  A23K10/18 ,  A23K50/40 ,  A61K9/0053 ,  A61K35/741 ,  A61K35/742 ,  A61K38/1735 ,  A61P3/04 ,  C12Q1/025 ,  A61K2035/115 ,  C12Q2600/106

Abstract: Bacterial species acting as biomarkers for obesity in domesticated cats and/or dogs are disclosed herein. Also disclosed are methods for diagnosing and/or treating cats and/or dogs having obesity or a predisposition to obesity as well as methods of screening for agents to treat or prevent obesity.

公开(公告)号：US20230398178A1

公开(公告)日：2023-12-14

申请号：US18334253

申请日：2023-06-13

Applicant: Massachusetts Institute of Technology

Inventor： Katharina Ribbeck ,  Laura L. Kiessling ,  Caroline Andrea Werlang ,  Spencer D. Brucks ,  Liubov Yakovlieva ,  Kelsey Morgan Wheeler

IPC: A61K38/17 ,  A61K31/7004 ,  A61K35/747 ,  A61K31/4164 ,  A61K47/64 ,  A61P31/04 ,  A61K31/7008 ,  A61K47/58

CPC classification number: A61K38/1735 ,  A61K31/7004 ,  A61K35/747 ,  A61K31/4164 ,  A61K47/64 ,  A61P31/04 ,  A61K31/7008 ,  A61K47/58

Abstract: Methods of treating or preventing a vaginal infection of Gardnerella vaginalis in a subject involve administering to the subject an effective amount of a composition. The composition can include one or more of galactose, D-fucose, or mucin 5B. The composition can include one or more of galactose, N-acetyl D-galactosamine, N-acetyl D-glucosamine, D-fucose, or mucin 5B bonded to a surface, such as a polymer surface.

公开(公告)号：US11712423B2

公开(公告)日：2023-08-01

申请号：US17222089

申请日：2021-04-05

Applicant: Nicholas L. Abbott ,  Christopher J. Murphy

Inventor： Nicholas L. Abbott ,  Christopher J. Murphy

IPC: A61K38/17 ,  A61K47/42 ,  A61K9/70 ,  A61K48/00 ,  A61K9/00 ,  A61K45/06 ,  A61K31/00 ,  A61K31/095 ,  A61K31/375 ,  A61K31/66 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/726 ,  A61K38/02 ,  A61K38/05

CPC classification number: A61K9/70 ,  A61K9/006 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0048 ,  A61K31/00 ,  A61K31/095 ,  A61K31/375 ,  A61K31/66 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/726 ,  A61K38/02 ,  A61K38/05 ,  A61K38/1735 ,  A61K45/06 ,  A61K47/42 ,  A61K48/0075

Abstract: The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.

公开(公告)号：US09950016B2

公开(公告)日：2018-04-24

申请号：US14127991

申请日：2012-06-25

Applicant: Timothy O'Brien ,  Frank Barry ,  Claire Kavanagh

Inventor： Timothy O'Brien ,  Frank Barry ,  Claire Kavanagh

IPC: A01N63/00 ,  A61K35/545 ,  A61K38/19 ,  A61K38/17 ,  A61K38/18 ,  A61K38/39 ,  A61K35/28 ,  A61K35/44 ,  A61K38/21 ,  A61K38/36 ,  A61L15/44 ,  A61L27/28 ,  A61L27/38 ,  A61L27/54 ,  A61L29/08 ,  A61L29/16

CPC classification number: A61K35/545 ,  A61K35/28 ,  A61K35/44 ,  A61K38/1709 ,  A61K38/1735 ,  A61K38/177 ,  A61K38/179 ,  A61K38/1891 ,  A61K38/19 ,  A61K38/195 ,  A61K38/217 ,  A61K38/363 ,  A61K38/39 ,  A61L15/44 ,  A61L27/28 ,  A61L27/3804 ,  A61L27/54 ,  A61L29/08 ,  A61L29/16

Abstract: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.

公开(公告)号：US20170290889A1

公开(公告)日：2017-10-12

申请号：US15484555

申请日：2017-04-11

Applicant: New York University

Inventor： P'ng Loke ,  Kenneth Cadwell ,  Deepshika Ramanan ,  Rowann Bowcutt

IPC: A61K38/20 ,  A61K35/62 ,  A61K35/74 ,  A61K38/17

CPC classification number: A61K38/20 ,  A61K35/62 ,  A61K35/74 ,  A61K38/1735 ,  A61K38/2026 ,  A61K38/2086 ,  C07K14/4727 ,  C07K14/54 ,  C07K14/5406 ,  C07K14/5437 ,  C07K2319/30 ,  A61K2300/00

Abstract: The present invention relates to the use of type 2 cytokines and mucins for increasing the amount or activity of bacterial species of the Clostridia class in the gastrointestinal tract, for treating dysbiosis in the gastrointestinal tract, for treating gastrointestinal and inflammatory disorders, and for promoting wound healing in the gastrointestinal tract.

公开(公告)号：US09675667B2

公开(公告)日：2017-06-13

申请号：US15018965

申请日：2016-02-09

Applicant: Massachusetts Institute of Technology

Inventor： Katharina Ribbeck ,  Nicole Lynn Kavanaugh ,  Julia Yin-Ting Co ,  Erica Shapiro

IPC: A61K35/74 ,  A61K38/17 ,  A61K47/42 ,  C12N1/20 ,  A61K9/20 ,  A61K9/00 ,  A61K9/06 ,  A01N63/02 ,  A23L29/00 ,  C12N1/16 ,  C12N1/38

CPC classification number: G01N33/68 ,  A01N63/02 ,  A23L29/065 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/06 ,  A61K9/20 ,  A61K35/74 ,  A61K38/14 ,  A61K38/1735 ,  A61K47/42 ,  C12N1/16 ,  C12N1/20 ,  C12N1/38 ,  G01N33/53 ,  G01N2500/10

Abstract: A method of altering intercellular interactions between a combination of microorganisms includes contacting a combination of different species of microorganisms with at least one mucin. Isolated compositions include a combination of microorganisms and at least one mucin. One microorganism of the combination inhibits cell growth or promotes cell death of at least one other microorganism of a different species in the combination. The combination of microorganisms with the mucin results an increase in cell growth or a reduction in cell death, respectively, of the at least one other microorganism.

公开(公告)号：US20160361438A1

公开(公告)日：2016-12-15

申请号：US15248902

申请日：2016-08-26

Applicant: CureVac AG

Inventor： Florian VON DER MÜLBE ,  Ingmar HOERR ,  Steve PASCOLO

IPC: A61K48/00 ,  A61K47/48 ,  A61K38/17 ,  C07K14/47

CPC classification number: A61K48/005 ,  A61K38/1735 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/193 ,  A61K38/28 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/0258 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K47/542 ,  A61K47/6455 ,  A61K48/00 ,  A61K48/0066 ,  A61K48/0075 ,  A61K48/0083 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/245 ,  C07K14/4727 ,  C07K14/4748 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N2310/334 ,  C12N2310/336 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2770/24122 ,  C12N2770/24134 ,  G16B20/00 ,  G16B30/00 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/416 ,  Y02A50/464 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.

公开(公告)号：US20150010495A1

公开(公告)日：2015-01-08

申请号：US14148161

申请日：2014-01-06

Applicant: GLYCOTOPE GMBH

Inventor： Steffen Goletz ,  Uwe Karsten

IPC: C07K14/47 ,  A61K45/06 ,  A61K39/00 ,  A61K38/17

CPC classification number: C07K14/4727 ,  A61K38/1735 ,  A61K39/0005 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3092 ,  C07K16/44

Abstract: The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumours. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumours.

Abstract translation: 本发明涉及能够在人体中产生免疫应答的产生或鉴定MUC1分子的方法。 本发明还涉及产生或鉴定含有能够在人体中产生免疫应答的MUC1分子的细胞，细胞系或细胞裂解物的方法。 本发明还涉及生产药物和诊断剂的方法。 还公开了通过根据本发明的方法获得的MUC1分子，细胞或细胞裂解物用于产生用于治疗或预防肿瘤的药物的用途。 进一步公开的是可以通过本发明的方法获得并且对人类具有免疫刺激作用的纯化的MUC1分子。 本发明还涉及MUC1抗体用于制备用于治疗或预防肿瘤的药物的用途。

公开(公告)号：US20140187474A1

公开(公告)日：2014-07-03

申请号：US14199846

申请日：2014-03-06

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Justin L. Sonnenburg

IPC: C07K14/47

CPC classification number: C07K14/4727 ,  A23L33/10 ,  A61K38/1735

Abstract: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.

Abstract translation: 描述了含有衍生自一种或多种营养适宜来源的粘蛋白聚糖的治疗剂型。